0.0168
+0.0006
+(3.70%)
As of 8:08:40 AM GMT+2. Market Open.
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Charlotte Fribert | CEO & Executive Director | -- | -- | 1967 |
| Ms. Ann-Sofie Taube | Chief Financial Officer | -- | -- | -- |
| Dr. Björn Löwenadler Ph.D. | Chief Business Officer | -- | -- | 1952 |
| Dr. Vidar Wendel-Hansen M.D., Ph.D. | Chief Medical Officer | -- | -- | 1959 |
Toleranzia AB
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 10
Description
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, it develops tolerogens proteins technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was incorporated in 2011 and is headquartered in Gothenburg, Sweden.
Corporate Governance
Toleranzia AB’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available